Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus

Antimicrobial Agents and Chemotherapy(2024)10.1128/aac.00174-24Source: DataRank Database

In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus is a research paper published in Antimicrobial Agents and Chemotherapy (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

bioproject

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.44)OA: bronzeTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Elena Shashkina,Natalia Kurepina,Vinicius Calado Nogueira de Moura ORCID,Charles L. Daley ORCID,Barry N. Kreiswirth ORCID

Live enrichment

PubMed:38557171 PMC:PMC11064484 OpenAlex:https://openalex.org/W4393387314

HHS | NIH | National Institute of Allergy and Infectious Diseases

Grant: R01AI141805

FWCI

1.44

Citation Percentile

0.8%

Citation Trend

2024

2025

bronzeLicense: https://doi.org/10.1128/ASMCopyrightv2

journalhttps://journals.asm.org/doi/pdf/10.1128/aac.00174-24?download=true

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.00174-24?download=true

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.00174-24

journalhttps://doi.org/10.1128/aac.00174-24

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38557171

Fields of Study

Mycobacterium research and diagnosisTuberculosis Research and EpidemiologyAntibiotic Resistance in Bacteria

MeSH Terms

Mycobacterium abscessusMeropenemCeftarolineAnti-Bacterial AgentsBoronic AcidsCefoxitinCephalosporinsHumansMicrobial Sensitivity TestsMycobacterium Infections, NontuberculousImipenembeta-Lactamase Inhibitors

Keywords

CefoxitinMicrobiologyMycobacterium abscessusMedicineAntibioticsIn vitroBiologyMycobacteriumBacteriaGeneticsStaphylococcus aureusPeptidoglycan SynthesisCrispr InterferenceΒ-lactamase InhibitorsVaborbactam

Sustainable Development Goals

SDG 0: Good health and well-being

In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus

FAIR Checklist

Authors (6)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)